Treatment of hepatitis C virus infection and associated glomerular disease

Treatment of hepatitis C virus infection and associated glomerular disease

Hepatitis C virus infection is a systemic disorder and can have various extrahepatic manifestations like hepatitis virus C associated glomerulonephritis. KDIGO recommends that all patients with hepatitis C virus infection be tested at least annually for proteinuria, hematuria and eGFR in order to de...

Full description

Bibliographic Details
Main Authors:	Delia-Georgiana Tudorovici, Mircea Penescu
Format:	Article
Language:	English
Published:	Amaltea Medical Publishing House 2020-09-01
Series:	Romanian Medical Journal
Subjects:	hepatitis c virus immunosuppression daas ckd glomerulonephritis
Online Access:	https://rmj.com.ro/articles/2020.3/RMJ_2020_3_Art-01.pdf

Similar Items

Glomerular Diseases Associated with Hepatitis C Virus Infection
by: Miller Sara, et al.
Published: (2000-01-01)

HEPATITIS C VIRUS – FROM UNKNOWN VIRUS TO A CURABLE DISEASE
by: Raluca Mihaela Dirtu, et al.
Published: (2019-06-01)

Resistance Mutations A30K and Y93N Associated with Treatment Failure with Sofosbuvir and Daclatasvir for Hepatitis C Virus Infection Non-Responder Patients: Case Reports
by: Vanessa D. Costa, et al.
Published: (2019-10-01)

Hepatitis C virus infection in nephrology patients
by: Lionel Rostaing, et al.
Published: (2013-10-01)

Micro-elimination of hepatitis C in patients with chronic kidney disease: an Egyptian single-center study
by: Tari George Michael, et al.
Published: (2022-07-01)

Evaluation of liver fibrosis and carotid intima-media thickness index (C-IMT) in patients with chronic hepatitis C virus before and after direct-acting antiviral treatment (DAA)
by: Raluca Mihaela Dirtu, et al.
Published: (2021-06-01)

Epidemiology, disease burden, and treatment strategies of chronic hepatitis C virus infections in Saudi Arabia in the new treatment paradigm shift
by: Abdulrahman A Aljumah, et al.
Published: (2016-01-01)

New treatment of hepatitis C (Direct Acting Antiviral)
by: Mohsen Akhondi-Meybodi
Published: (2019-10-01)

A Review on Extrahepatic Manifestations of Chronic Hepatitis C Virus Infection and the Impact of Direct-Acting Antiviral Therapy
by: Cesare Mazzaro, et al.
Published: (2021-11-01)

Safety and efficacy of elbasvir/grazoprevir for the treatment of chronic hepatitis C: current evidence
by: Morikawa K, et al.
Published: (2018-09-01)

Effectiveness of elbasvir/grazoprevir plus ribavirin for hepatitis C virus genotype 1a infection and baseline NS5A resistance
by: Deanna D. Hill, et al.
Published: (2023-03-01)

Long-Term Impact of Direct-Acting Antivirals on Liver Fibrosis and Survival in HCV-Infected Liver Transplant Recipients
by: Martina Gambato, et al.
Published: (2023-08-01)

TREATMENTS OF HEPATITIS C VIRUS LIVER CIRRHOSIS WITH PEGYLAT INTERFERON-RIBAVIRIN AND INTERFERON FREE – COMPARATIVE STUDY
by: S.A. Florescu, et al.
Published: (2016-12-01)

Efficacy of Interferonfree treatment for patients with chronic hepatitis C virus
by: Valeria Muntean, et al.
Published: (2019-05-01)

Hepatitis C virus pharmacogenomics in Latin American populations: implications in the era of direct-acting antivirals
by: Trinks J, et al.
Published: (2017-03-01)

Direct-Acting Antiviral Agents for Hepatitis C Virus Infection—From Drug Discovery to Successful Implementation in Clinical Practice
by: Christopher Dietz, et al.
Published: (2022-06-01)

Cryoglobulinemic glomerulonephritis: an extrahepatic manifestation of hepatitis C virus (HCV) infection
by: Giovanni Garini, et al.
Published: (2007-12-01)

Assessment of carotid atherosclerosis in Egyptian chronic hepatitis C patients after treatment by direct-acting antiviral drugs
by: Marwa Ahmed Mohamed, et al.
Published: (2022-09-01)

Clinicopathological study of mixed cryoglobulinemic glomerulonephritis secondary to hepatitis B virus infection
by: Chao Li, et al.
Published: (2020-09-01)

Real-Life Data of Chronic Hepatitis C Patients Treated with Direct-Acting Oral Antivirals: A Single-Center Study
by: Umut Devrim Binay, et al.
Published: (2023-05-01)

Hepatitis C Virus Infection and Renal Disorders
by: Maurizio Salvadori, et al.
Published: (2019-01-01)

Direct Antiviral Treatments for Hepatitis C Virus Have Off-Target Effects of Oncologic Relevance in Hepatocellular Carcinoma
by: Catia Giovannini, et al.
Published: (2020-09-01)

Decreased expression of interferon‐stimulated genes in B cells of patients with chronic hepatitis C during interferon‐free therapy potentially suggests the eradication of hepatitis C virus in the B cells: A cohort study
by: Jun Arai, et al.
Published: (2020-09-01)

Prevalence of resistance-associated substitutions to direct-acting antiviral agents in hemodialysis and renal transplant patients infected with hepatitis C virus
by: Tavares RCF, et al.
Published: (2018-10-01)

Therapy with interferon-alpha plus ribavirin for membranoproliferative glomerulonephritis induced by hepatitis C virus
by: Edmundo P.A. Lopes, et al.

Therapy with interferon-a plus ribavirin for membranoproliferative glomerulonephritis induced by hepatitis C virus
by: Lopes Edmundo P.A., et al.
Published: (2003-01-01)

Risk Factors Contributing to the Occurrence and Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus Patients Treated with Direct-Acting Antivirals
by: Sara Kishta, et al.
Published: (2020-06-01)

Real‐world effectiveness of direct‐acting antiviral agents for chronic hepatitis C patients with genotype‐2 infection after completed treatment
by: Tzu‐Sheng Cheng, et al.
Published: (2021-04-01)

Hepatocellular Carcinoma Recurrence after Hepatitis C Virus Therapy with Direct-Acting Antivirals. A Systematic Review and Meta-Analysis
by: Leonardo Frazzoni, et al.
Published: (2021-04-01)

Outcomes of a tertiary-based innovative approach to engage primary care providers in provision of hepatitis C treatment in community settings
by: Davoud Pourmarzi, et al.
Published: (2019-10-01)

Glomerular Diseases as Extrahepatic Manifestations of Hepatitis C Virus Infection
by: Dede SIT, et al.
Published: (2013-12-01)

Pre-Senescence Induction in Hepatoma Cells Favors Hepatitis C Virus Replication and Can Be Used in Exploring Antiviral Potential of Histone Deacetylase Inhibitors
by: Alsu Z. Malikova, et al.
Published: (2021-04-01)

National Brazilian survey on the outcomes of hepatitis c retreatment in patients non-responders to direct antiviral agents
by: Maria Lúcia Gomes Ferraz, et al.
Published: (2022-07-01)

Hepatitis B virus-targeting sodium taurocholate cotransporting polypeptide mediates HBV infection and damage in human renal podocytes
by: Lifen Wang, et al.
Published: (2024-03-01)

Updated Clinical Guidelines on the Management of Hepatitis C Infection in Children
by: Chaowapong Jarasvaraparn, et al.
Published: (2024-02-01)

Hepatitis C Vaccination: Where We Are and Where We Need to Be
by: Vignan Manne, et al.
Published: (2021-12-01)

Retreatment of patients with chronic hepatitis C, subtype 3a, and cirrhosis, who previously failed a regimen containing NS5A inhibitors with sofosbuvir/velpatasvir plus ribavirin for 24 weeks
by: Sergii V. Fedorchenko, et al.
Published: (2023-06-01)

Characterization of a Novel Hepatitis C Subtype, 6xj, and Its Consequences for Direct-Acting Antiviral Treatment in Yunnan, China
by: Yuanyuan Jia, et al.
Published: (2021-09-01)

Rituximab in glomerular diseases: a case series and narrative review
by: Inês Duarte, et al.
Published: (2021-12-01)

Hepatitis C Virus (HCV)-Ribonucleic Acid (RNA) As a Biomarker for Lymphoid Malignancy with HCV Infection
by: Yutaka Tsutsumi, et al.
Published: (2023-05-01)